Results 21 to 30 of about 5,544 (172)
Experience with canakinumab in a patient with gout and IgA nephropathy
Современная ревматология, 2019 The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj +1 more source
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]
Journal of General Internal Medicine, 2017 Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie +5 more
openaire +4 more sources
Kidney & Blood Pressure Research, 2018 Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano +5 more
doaj +1 more source
PLoS ONE, 2019 Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj +1 more source
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +1 more source
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? [PDF]
Exploration of Musculoskeletal DiseasesCo-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares
Edward Roddy +2 more
doaj +1 more source
Arthritis Research & Therapy, 2022 Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life.
John K. Botson +5 more
doaj +1 more source
Comparison Between Early-Onset and Common Gout: A Systematic Literature Review
Rheumatology and Therapy, 2023 Introduction Gout is an inflammatory, metabolic disease associated with a high comorbidity burden including cardiovascular disease, hypertension, type 2 diabetes, hyperlipidemia, renal disease, and metabolic syndrome.
Anthony J. Amatucci +3 more
doaj +1 more source
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]
The Permanente Journal, 2018 Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy +3 more
openaire +2 more sources
Advances in Rheumatology, 2022 Objective The objective was to evaluate whether initiation of urate-lowering treatment (ULT) during an acute gout flare prolonged the current episode.
Ertao Jia +12 more
doaj +1 more source